newsfilter
← Latest News
GlobeNewswire·

LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

• LIBRA trial designed to support registration in China• Topline results expected in the fourth quarter of 2023 SHANGHAI and PRINCETON, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a